Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study
The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).
ctDNA Monitoring Can Predict Early Melanoma Recurrence Following Resection
Data come from patients with stage 3 melanoma enrolled in a phase 3 randomized trial and showed that detection of circulating tumor DNA (ctDNA) prior to adjuvant systemic therapy can predict risk of early recurrence.
Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL
Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).
Statins May Improve Survival Among Patients With CLL/SLL Receiving Ibrutinib
The findings come from a review of 4 randomized clinical trials, which found that statin use at the start of treatment was associated with improved cancer-related survival, overall survival, and progression-free survival.
Acalabrutinib Combos Improve PFS vs CIT in First-Line CLL
Acalabrutnib plus venetoclax, with or without obinutuzumab, improved progression-free survival (PFS) compared with chemoimmunotherapy (CIT) in patients with untreated chronic lymphocytic leukemia (CLL), meeting the phase 3 AMPLIFY study’s primary endpoint.
Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS
A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic syndromes (MDS) with the mutation.
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials
Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).
Researchers Characterize Defining Feature of Pediatric AML Subtype
Recently recognized by the World Health Organization, acute myeloid leukemia (AML) with t(7;12)(q36;p13) has previously been associated with MNX1 and ETV6 signaling, although MNX1::ETV6 fusion transcripts have only been confirmed in approximately half of cases.